Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2006-01-24
2006-01-24
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C435S325000, C435S366000, C424S093100, C424S093200, C424S093600
Reexamination Certificate
active
06989268
ABSTRACT:
This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with thymidine kinase metabolite in order to be effective).
REFERENCES:
patent: 6410010 (2002-06-01), Zhang et al.
patent: WO 94/24297 (1994-10-01), None
Berkner, K. L., Current Topics in Microbiology and Immunology, 1992, vol. 158, pp. 39-66.
Aiello et al., “Adenovirus 5 DNA Sequences Present and RNA Sequences Transcribed in Transformed Human Embryo Kidney Cells (HEK-Ad-5 or 293),”Virology94:460-469 (1979).
Aulitzky et al., “Recombinant Tumour Necrosis Factor Alpha administered Subcutaneously or Intramuscularly for Treatmentof Advanced Malignant Disease: a Phase I Trial,”Eur. J. Cancer27(4):462-467 (1991).
Austin et al., “A First Step in the Development of Gene Therapy for Colorectal Carcinoma: Cloning, Sequencing, and Expression ofEscherichia coliCytosine Deaminase,”Eur. J. Cancer27(4):462-467 (1991).
Bacchetti et al., “Inhibition of cell proliferation by an adenovirus vector expressing the human wild type p53 protein,”Int. J. Oncology3:781-788 (1993).
Baker et al., “Suppression of Human Colrectal Carcinoma Cell Growth by Wild-Type p53,” 249:912-915 (1990).
Bartek et al., “Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies,”Oncogene6:1699-1703 (1991).
Berkner et al., “Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant,”Nucleic Acids Research13(3):841-857 (1985).
Boshart et al., “A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus,”Cell41:521-530 (1985).
Bressac et al., “Abnormal structure and expression of p53 gene in human hepatocellular carcinoma,”Proc. Natl. Acad. Sci. U.S.A.87:1973-1977 (1990).
Caruso et al., “Regression of established macroscopic liver metastatses after in situ transduction of a suicide gene,”Proc. Natl. Acad. Sci. U.S.A.90:7024-7028 (1993).
Casey et al.,Oncogene6(10):1791-1797 (1991).
Challberg et al.,Proc. Natl. Acad. Sci. U.S.A.76:655-659.
Chen et al., “Genetic Mechanisms of Tumor Supression by the Human p53 Gene,”Science250:1576-1580 (1990).
Chen et al., “Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate,”OncogeneH:1799-1805 (1991).
Cheng et al., “Suppression of Acute Lymphoblastic Leukemia by the Human Wild-Type p53 Gene,”Cancer Research52:222-226 (1992).
Colby et al., “Adenovirus Type 5 Virions Can be Assembled in Vivo in the Absence of Detectable Polypeptide IX,”Virology39:977-980 (1981).
Culver et al., “In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors,”Science256:1550-1552 (1992).
Culver et al., “Lymphocytes as a cellular vehicle for gene therapy in mouse and man,”Proc. Natl. Acad. Sci. U.S.A.88:3155-3159 (1991).
Demetri et al., “A Phase I Trial of Recombinant Human Tumor Necrosis Factor and Interferon-Gamma: Effects of Combination Cytokine Administration In Vivo,”J. Clin. Oncol.7(10):1545-1553.
Diller et al., “p53 Functions as a Cell cycle Control Protein in Osteosarcomas,”Mol. Cell Biol.10:5772-5781 (1990).
El-Deiry et al., “WAF1, a Potential Mediator of p53 Tumor Suppression,”Cell75:817-825 (1993).
Ezzidine et al., “Selective Killing of Glioma Cells in Culture and in Vivo by Retrovirus Transfer of the Herpes Simplex Virus Thymidine Kinase Gene,”The New Biologist3:608-614 (1991).
Feinstein et al., “Expression of the normal p53 gene induces differentiation of K562 cells,”Oncogene7;1853-1857 (1992).
Freeman et al., “The ‘Bystander Effect’: Tumor REgression When a Fraction of the Tumor Mass is Genetically Modified,”Cancer Res.53:5274-5283 (1993).
Ghosh-Choudhury et al., “Protein IX, a minor component of hte human adenovirus capsid, is essential for the packaging of full length genomes,”EMBO J.6:1733-1739 (1987).
Gooding et al., “Molecular Mechanisms by which Adenoviruses counteract Antiviral Immune Defenses,”Crit. REv. Immunol.10:53-71 (1990).
Graham et al., “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,”Virology52:456-467 (1973).
Graham and Prevec,Vaccines: New Approaches to Immunological ProblemsR.W. Ellis (ed.), Boston, Butterworth-Heinemann, 363-369 (1992).
Haj-Ahmad et al., “Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene,”J. Virol.57(1):267-274 (1986).
Heuvel et al., “Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells,”EMBO J.9:2621-2629 (1990).
Hock et al., “Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ,”Proc. Natl. Acad. Sci. U.S.A.90:2774-2778 (1992).
Hollstein et al., “p53 Mutations in Human Cancers,”Science253:49-53 (1991).
Horwitz, “Adenoviridae and Their Replication,”VirologyB.V. Fields (ed.) New York, Raven Press, 1679-1721 (1990).
Horvath, et al., “Nonpermissivity of Human Peripheral Blood Lymphocytes to Adenovirus Type 2 Infection,”J. Virol.62:341-345 (1988).
Huang et al., “A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product,”Nature350:160-162 (1991).
Huber et al., “Retroviral -mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy,”Proc. Natl. Acad. Sci. U.S.A.88:8039-8043 (1991).
Hunter, “Braking the Cycle,”Cell75:839-841 (1993).
Jones et al., “Isolation of Adenovirus Type 5 Host Range Deletion Mutants Defective for Transformation of Rat Embryo Cells,”Cell17:683-689 (1979).
Kamb et al., “A Cell Cycle Regulator Potentially Involved in Genesis of Many tumor Types,”Science264:436-440 (1994).
Kuerbitz et al., “Wild-type p53 is a cell cycle checkpoint determinant following irradation,”Proc. Natl. Acad. Sci. U.S.A.89:7491-7495 (1992).
Landmann et al., “Prolonged Interferon-γ Application by Subcutaneous Infusion in Cancer Patients: Differential Response of Serum CD14, Neopterin, and Monocyte HLA Class I and II Antigens,”J. Interferon Res.12(2):103-111 (1992).
Lane, “p53, guardian of the genome,”Nature358:15-16 (1992).
Lee et al., “Human Retinoblastoma Susceptibility Gene: cloning, identification, and sequence,”Science235:1394-1399 (1987).
Lemaistre et al., Therapeutic effects of genetically engineered toxin.
Lemarchand, P., “Adenovirus-mediated transfer of a recombinant human α1-antitrypsin cDNA to human endothelial cells,”Proc. Natl. Acad. Sci. U.S.A.89:6482-6486 (1992).
Levine, A.J., “The Tumor Suppressor Genes,”Annu. Rev. Biochem.62:623-651 (1993).
Lowe et al., “p53 is required for radiation-induced apoptosis in mouse thymocytes,”Nature362:847-852 (1993).
Lowe et al., “p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents,”Cell74:957-967 (1993).
Mercer et al., “Nega
Gregory Richard J.
Maneval Daniel C.
Wills Ken N.
Canji Inc.
Guzo David
LandOfFree
Recombinant adenoviral vector and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant adenoviral vector and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant adenoviral vector and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3576102